[{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"7f1ad480-25c7-4c95-b0bc-1138e8d8a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT03076554","created_at":"2021-01-18T15:09:28.588Z","updated_at":"2025-02-25T16:51:49.925Z","phase":"Phase 2","brief_title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","source_id_and_acronym":"NCT03076554","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/19/2017","start_date":" 04/19/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-04"},{"id":"f33d52c2-9a8f-4b5c-acef-4121e6304fc8","acronym":"CA209-982","url":"https://clinicaltrials.gov/study/NCT03583086","created_at":"2021-01-18T17:37:36.257Z","updated_at":"2025-02-25T14:27:15.271Z","phase":"Phase 1/2","brief_title":"Phase I/II Eval Safety \u0026 Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","source_id_and_acronym":"NCT03583086 - CA209-982","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" EGFR • PD-L1 • BRAF • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 04/27/2024","study_completion_date":" 04/27/2024","last_update_posted":"2024-10-08"},{"id":"a2435d86-98de-4112-83d0-5bc0d0144cd7","acronym":"PECATI","url":"https://clinicaltrials.gov/study/NCT04710628","created_at":"2021-01-19T20:52:22.443Z","updated_at":"2025-02-25T16:11:03.589Z","phase":"Phase 2","brief_title":"Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents","source_id_and_acronym":"NCT04710628 - PECATI","lead_sponsor":"MedSIR","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 09/21/2021","start_date":" 09/21/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-08-08"},{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"47aa2393-a124-415e-825e-d17be7197efa","acronym":"NCI-2018-00192","url":"https://clinicaltrials.gov/study/NCT03463460","created_at":"2021-01-18T17:04:23.138Z","updated_at":"2024-07-02T16:35:14.545Z","phase":"Phase 2","brief_title":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","source_id_and_acronym":"NCT03463460 - NCI-2018-00192","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sunitinib"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"f53f42a9-ecf7-4d67-b3af-c5c26772cf8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05255965","created_at":"2022-02-25T17:52:49.421Z","updated_at":"2024-07-02T16:35:18.923Z","phase":"","brief_title":"IL-8+ naïve T Cells as a Biomarker for Thymoma Identification","source_id_and_acronym":"NCT05255965","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"],"overall_status":"Recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-19"},{"id":"d35bf2f8-c72c-4e41-b03f-2a4b88237830","acronym":"LuPARP","url":"https://clinicaltrials.gov/study/NCT04375267","created_at":"2021-01-18T21:08:12.416Z","updated_at":"2025-02-25T15:43:58.882Z","phase":"Phase 1","brief_title":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","source_id_and_acronym":"NCT04375267 - LuPARP","lead_sponsor":"Vastra Gotaland Region","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-14"},{"id":"3570464a-977a-4c4b-b9ce-da03668a6a6f","acronym":"LEVEL","url":"https://clinicaltrials.gov/study/NCT05918302","created_at":"2023-06-26T14:09:09.001Z","updated_at":"2024-07-02T16:35:30.525Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","source_id_and_acronym":"NCT05918302 - LEVEL","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-02"},{"id":"3ce69970-94bf-45cb-9554-dc5a804c3a24","acronym":"Artemis","url":"https://clinicaltrials.gov/study/NCT05832827","created_at":"2023-04-27T14:05:02.007Z","updated_at":"2025-02-25T16:18:45.546Z","phase":"Phase 2","brief_title":"First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)","source_id_and_acronym":"NCT05832827 - Artemis","lead_sponsor":"National Cancer Center, Japan","biomarkers":" KIT • CD5 • TP63","pipe":" | ","alterations":" CD5 positive","tags":["KIT • CD5 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/04/2023","start_date":" 09/04/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-10-20"},{"id":"ec7f3f07-9bc3-4dd0-a1ea-5b794d106fef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06086327","created_at":"2023-10-17T15:12:41.211Z","updated_at":"2024-07-02T16:35:33.342Z","phase":"Phase 1","brief_title":"Application of 68Ga-Pentixafor PET/CT for Thymoma","source_id_and_acronym":"NCT06086327","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/22/2023","start_date":" 06/22/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-17"},{"id":"aa8467ad-c072-4b95-8f7a-4e50666ebdc6","acronym":"FAPI PET RDRC","url":"https://clinicaltrials.gov/study/NCT04459273","created_at":"2023-10-21T07:12:20.148Z","updated_at":"2024-07-02T16:35:33.555Z","phase":"Phase 1","brief_title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","source_id_and_acronym":"NCT04459273 - FAPI PET RDRC","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-13"},{"id":"b8174b4e-6461-468f-8626-7e5c32664cd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01385722","created_at":"2021-01-18T05:41:06.176Z","updated_at":"2024-07-02T16:35:42.634Z","phase":"","brief_title":"Molecular Analysis of Thoracic Malignancies","source_id_and_acronym":"NCT01385722","lead_sponsor":"Stanford University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 1000","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 06/01/2031","primary_completion_date":" 06/01/2031","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2023-07-19"},{"id":"408ec697-317c-432e-9870-e974167b3c92","acronym":"PUTNET","url":"https://clinicaltrials.gov/study/NCT04276597","created_at":"2021-01-18T20:46:10.712Z","updated_at":"2024-07-02T16:35:53.562Z","phase":"Phase 2","brief_title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","source_id_and_acronym":"NCT04276597 - PUTNET","lead_sponsor":"Excel Diagnostics and Nuclear Oncology Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2023-03-10"},{"id":"ae216550-3a80-4c69-8c1c-7c8b08c85f84","acronym":"NIVOTHYM","url":"https://clinicaltrials.gov/study/NCT03134118","created_at":"2021-01-18T15:26:33.976Z","updated_at":"2024-07-02T16:35:55.038Z","phase":"Phase 2","brief_title":"Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)","source_id_and_acronym":"NCT03134118 - NIVOTHYM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/11/2018","start_date":" 04/11/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-02-21"},{"id":"fa288c29-592d-4dfb-ba55-267713dd3131","acronym":"DUET-2","url":"https://clinicaltrials.gov/study/NCT03517488","created_at":"2021-01-18T17:18:50.722Z","updated_at":"2024-07-02T16:35:59.763Z","phase":"Phase 1","brief_title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03517488 - DUET-2","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2022-12-01"},{"id":"31829fe8-d30b-437f-95cb-00ae52e87483","acronym":"","url":"https://clinicaltrials.gov/study/NCT02049047","created_at":"2021-01-17T17:29:43.082Z","updated_at":"2024-07-02T16:36:04.172Z","phase":"Phase 2","brief_title":"Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy","source_id_and_acronym":"NCT02049047","lead_sponsor":"Armando Santoro, MD","biomarkers":" PTEN • mTOR","pipe":"","alterations":" ","tags":["PTEN • mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 02/01/2011","start_date":" 02/01/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2022-09-10"},{"id":"e842207a-d53c-4fac-888f-0398a7b98320","acronym":"","url":"https://clinicaltrials.gov/study/NCT04554524","created_at":"2021-01-18T21:46:26.560Z","updated_at":"2024-07-02T16:36:39.521Z","phase":"Phase 4","brief_title":"Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma","source_id_and_acronym":"NCT04554524","lead_sponsor":"Tang-Du Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 07/30/2024","study_completion_date":" 07/30/2024","last_update_posted":"2020-10-28"},{"id":"d1276a71-346e-434a-9c65-2d109eb5f04b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02607631","created_at":"2021-01-18T12:39:56.355Z","updated_at":"2024-07-02T16:36:43.432Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor","source_id_and_acronym":"NCT02607631","lead_sponsor":"Samsung Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2020-07-09"},{"id":"4b0f6cb1-7aff-4d10-960d-2eaaf780f325","acronym":"","url":"https://clinicaltrials.gov/study/NCT02364076","created_at":"2021-01-18T11:15:21.067Z","updated_at":"2025-02-25T16:14:28.467Z","phase":"Phase 2","brief_title":"Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma","source_id_and_acronym":"NCT02364076","lead_sponsor":"Georgetown University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • epacadostat (INCB024360)"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2019-12-13"},{"id":"1d17430c-1429-4991-b902-bba8b2ceee07","acronym":"","url":"https://clinicaltrials.gov/study/NCT02948855","created_at":"2021-01-18T14:28:59.625Z","updated_at":"2024-07-02T16:37:10.649Z","phase":"","brief_title":"Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases","source_id_and_acronym":"NCT02948855","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" NOTCH2","pipe":"","alterations":" ","tags":["NOTCH2"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 05/01/2018","primary_completion_date":" 05/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-05-18"}]